两代酶联免疫试剂在男男性行为人群HIV检测中的应用

目的通过使用第四代与第三代艾滋病病毒(HIV)抗体酶联免疫试剂检测结果及核酸检测结果的比较,评估其在天津市男性性行为人群(MSM)HIV感染筛查中的应用效果。方法对天津市某区自愿咨询检测点进行咨询检测的男男性行为人群用EDTA抗凝管采集血液样品,同时使用两代HIV抗体筛查试剂进行检测,阳性者进行确证检测,两种筛查试剂检测结果均为阴性的样品,采用集合核酸检测方法进行检测。结果共计检测MSM人群血液样本2 065份,共对87份样品进行了确证试验,1 978份HIV抗体筛查阴性样品经核酸检测,有1份集合样品呈阳性。HIV抗体确证试验为阴性和不确定的6份样品,进行单份核酸检测,有4份HIV-1RNA阳性,病毒载量检测结果均符合HIV急性感染特征。此次研究中的MSM人群HIV感染率为4.16%(86/2 065),95%可信区间3.34%～5.12%。发现5例HIV急性感染者,估计该人群年发病率为3.16%,95%可信区间1.01%～7.35%。使用第三代抗体试剂进行筛查时,总费用为148 360元,其敏感性为94.2%(81/86)、特异性为100%,发现HIV感染者的单位成本为1 832.6元。使用第四代抗体试剂进行筛查时,总费用为166 080元,其敏感性为98.8%(85/86)、特异性为99.9%(1 977/1 979),发现HIV感染者的单位成本为1 953.9元。结论此次研究估测该人群的HIV感染年发病率为1.01%～7.35%,提示其高危性行为程度较高。在该人群中,使用第四代试剂筛查时,HIV感染者发现数比使用第三代试剂增加4.9%,发现HIV感染者的单位成本增加6.2%,提示具有推广应用价值。     

2011-2015年芜湖市男男性行为人群安全套使用状况及影响因素分析

目的 了解2011-2015年芜湖市男男性行为人群（men who have sex with men,MSM）安全套使用情况及其影响因素,为当地制订该人群的艾滋病防治措施提供依据。方法 利用《全国艾滋病哨点监测方案》的问卷,在2011-2015年哨点监测期内对约400例MSM进行问卷调查,收集有关艾滋病知识、高危行为等资料,并采集血液进行艾滋病、梅毒、丙肝检测。结果 5年共调查MSM 2 037例。调查对象中最近半年发生肛交性行为安全套每次使用率分别是23.24%、38.13%、37.41%、47.15%和82.22%,呈现逐年上升趋势（χ_趋势2=266.778,P<0.001）;多因素Logistic回归分析结果显示最近半年发生同性商业性行为、与女性发生性行为、最近一年诊断过性病的调查对象最近半年每次肛交性行为坚持使用安全套比例较低;血清学检测结果显示调查对象艾滋病、梅毒和丙肝检测阳性率分别是5.84%、12.37%和0.69%,5年的艾滋病阳性率分别是4.36%、3.36%、6.48%、6.48%和8.64%。结论 芜湖市MSM安全套使用率有所提升,但仍然不高;艾滋病、梅毒感染率还在逐年上升,应继续加强该人群针对性宣传教育和行为干预工作。     

妊娠晚期孕妇抑郁与睡眠质量的相关性研究

目的 了解妊娠晚期孕妇抑郁和睡眠质量的现况及其影响因素,探讨妊娠晚期孕妇抑郁与睡眠质量的相关性。方法 选择中卫市2所医院535名符合调查要求的孕妇进行问卷调查,采用匹兹堡睡眠质量指数量表（pittsburgh sleep quality index,PSQI）和抑郁自评量表（self-rating depression scale,SDS）评定孕妇睡眠质量及抑郁。结果 535名孕妇抑郁检出率为34.2%,睡眠障碍的检出率为20.6%。有抑郁的孕妇睡眠障碍检出率（29.0%）高于无抑郁的孕妇（16.2%）,差异有统计学意义（χ2=12.018,P=0.001）。PSQI总分和SDS得分呈正相关（r=0.680,P<0.001）。文化程度低、夫妻关系差、有孕期并发症、睡眠障碍是妊娠晚期孕妇抑郁的危险因素。有孕期并发症、担忧孩子健康、抑郁是妊娠晚期孕妇睡眠障碍的危险因素。结论 妊娠晚期孕妇睡眠质量与抑郁呈正相关,应采取综合性干预措施改善妊娠晚期孕妇的抑郁情绪和睡眠质量。     

云南省文山州HIV感染者抗病毒治疗脱失影响因素的定性研究

目的 了解云南省文山州人类免疫缺陷病毒（human immunodeficiency virus,HIV）感染者抗病毒治疗（antiretroviral therapy,ART）脱失的影响因素。方法 根据"研究对象最大差异"原则,采用立意抽样的方法从文山州文山市和马关县的三个ART门诊选取ART脱失者、脱失者家属、ART工作人员进行深入定性访谈,从个人、家庭、门诊三个层面探讨ART脱失的影响因素,样本量根据信息饱和原则确定。结果 本次共访谈43名ART脱失者,平均年龄为（47.8±15.6）岁;还访谈了7名脱失者家属和11名ART工作人员。结果显示,药物副反应、对ART认知不正确、担心暴露、歧视、服药心理负担大、采用偏方替代治疗是个人层面影响治疗脱失的因素,家庭支持、ART可及性、门诊医疗服务水平是影响治疗脱失的外部因素。结论 影响文山州HIV感染者ART脱失的因素包括药物副反应、ART认知、心理因素、家庭支持、门诊服务水平和ART可及性,应从个人、家庭和门诊层面采取综合干预措施降低治疗脱失。     

德宏州HIV单阳夫妻双方丙型肝炎病毒感染状况及影响因素

目的 了解云南省德宏州人类免疫缺陷病毒（human immunodeficiency virus,HIV）单阳夫妻双方（HIV感染者及其阴性配偶）丙型肝炎病毒（viral hepatitis C,HCV）感染情况及其影响因素。方法 收集HIV单阳夫妻的人口学特征、行为学指标和血样,并进行HCV抗体检测,应用χ2检验和Logistic回归分析不同因素对HCV感染率的影响。结果 582对HIV单阳家庭中,夫妻双方均感染HCV有12对（2.1%）,仅一方感染HCV有138对（23.7%）。HIV阳性配偶HCV感染率为23.2%,HIV阴性配偶HCV感染率为4.6%,差异有统计学意义（χ2=83.641,P<0.001）。男性配偶中,HIV阳性者HCV感染率为32.6%,HIV阴性者HCV感染率为4.6%,差异有统计学意义（χ2=56.828,P<0.001）;女性配偶中,HIV阳性者HCV感染率为4.6%,HIV阴性者HCV感染率为4.7%,二者无统计学差异（χ2<0.001,P=0.958）。多因素Logistic回归分析显示,男性配偶中35~46岁、景颇族、HIV阳性、吸毒是HCV感染的危险因素。结论 德宏州HIV单阳夫妻特别是HIV阳性男性配偶中HCV感染率高,HCV存在性传播的潜在威胁,有必要加强对HIV单阳家庭的丙型肝炎防治,对男性和女性配偶采取针对性的预防干预措施。     

北京市2005-2015年艾滋病抗病毒治疗患者生存及其影响因素

目的 分析北京市2005-2015年间艾滋病抗病毒治疗患者的生存情况及其影响因素,评估北京市免费艾滋病抗病毒治疗效果。方法 采用回顾性队列研究方法,利用艾滋病综合防治信息系统中2005-2015年进入队列的病人数据资料进行分析,应用寿命表法计算研究对象的生存率、利用乘积极限法计算研究对象截止观察终点的平均生存时间、采用COX比例风险回归模型分析研究对象生存时间的影响因素。结果 共纳入研究对象10 077例,平均生存时间是131.24个月（130.48~132.00个月）,总病死率为0.45/100人年,治疗1、5、10年累计生存率分别为99.25%、98.22%、96.01%。经多因素调整后分析发现,患者开始治疗时的年龄、感染途径、基线CD4+T淋巴细胞计数分组为生存时间的影响因素（均有P<0.05）。结论 北京市免费艾滋病抗病毒治疗患者病死率低,生存率高,治疗效果好;影响北京市免费艾滋病抗病毒治疗患者生存时间的因素为开始治疗时年龄、感染途径、基线CD4+T淋巴细胞计数（均有P<0.05）。     

Protective behaviours among young African American women with non-monogamous sexual partners

In the USA, partner non-monogamy is reported to be more common among African American women than White women and may contribute to African American women’s increased risk for HIV and other sexually transmitted infections (STIs). Few studies have explicitly and comprehensively described the protective behaviours that African American women employ with non-monogamous partners to reduce their HIV risk. We conducted interviews to examine protective behaviours among 11 African American women aged 18–24 years who perceived that a partner in the preceding 12 months had another sex partner. Participants described three types of partnerships with 29 non-monogamous men; these partnerships clustered into three categories. Narrative analysis revealed an overall paucity of protective behaviours with non-monogamous partners. Protective behaviours (i.e. communication and condom use) were informed by partnership type, rather than perceptions of non-monogamy. There were few instances in which partner non-monogamy motivated women to terminate sex partnerships. Rather, these decisions were often motivated by changes in other relationship dynamics. To address HIV/STI risk related to partner non-monogamy, HIV prevention strategies for young African American women should emphasise the importance of condom use in all non-marital partnership types. Interventions where testing is available may be effective for women who frequently test for HIV/STIs but do not use condoms.     

Differences in Selected HIV Care Continuum Outcomes Among People Residing in Rural,Urban, and Metropolitan Areas—28 US Jurisdictions

Purpose

The HIV care continuum is used to monitor success in HIV diagnosis and treatment among persons living with HIV in the United States. Significant differences exist along the HIV care continuum between subpopulations of people living with HIV; however, differences that may exist between residents of rural and nonrural areas have not been reported.

Methods

We analyzed the Centers for Disease Control and Prevention's National HIV Surveillance System data on adults and adolescents (≥13 years) with HIV diagnosed in 28 jurisdictions with complete reporting of HIV‐related lab results. Lab data were used to assess linkage to care (≥1 CD4 or viral load test ≤3 months of diagnosis), retention in care (≥2 CD4 and/or viral load tests ≥3 months apart), and viral suppression (viral load <200 copies/mL) among persons living with HIV. Residence at diagnosis was grouped into rural (<50,000 population), urban (50,000‐499,999 population), and metropolitan (≥500,000 population) categories for statistical comparison. Prevalence ratios and 95% CI were calculated to assess significant differences in linkage, retention, and viral suppression.

Findings

Although greater linkage to care was found for rural residents (84.3%) compared to urban residents (83.3%) and metropolitan residents (81.9%), significantly lower levels of retention in care and viral suppression were found for residents of rural (46.2% and 50.0%, respectively) and urban (50.2% and 47.2%) areas compared to residents of metropolitan areas (54.5% and 50.8%).

Conclusions

Interventions are needed to increase retention in care and viral suppression among people with HIV in nonmetropolitan areas of the United States.     

Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings,National Institute of Allergy and Infectious Diseases,Bethesda, Maryland,USA, May 21, 2015

On May 21st, 2015, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop on delivery devices for nucleic acid (NA) as vaccines in order to review the landscape of past and future technologies for administering NA (e.g., DNA, RNA, etc.) as antigen into target tissues of animal models and humans. Its focus was on current and future applications for preventing and treating human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) disease, among other infectious-disease priorities. Meeting participants presented the results and experience of representative clinical trials of NA vaccines using a variety of alternative delivery devices, as well as a broader group of methods studied in animal models and at bench top, to improve upon the performance and/or avoid the drawbacks of conventional needle-syringe (N–S) delivery. The subjects described and discussed included (1) delivery targeted into oral, cutaneous/intradermal, nasal, upper and lower respiratory, and intramuscular tissues; (2) devices and techniques for jet injection, solid, hollow, and dissolving microneedles, patches for topical passive diffusion or iontophoresis, electroporation, thermal microporation, nasal sprayers, aerosol upper-respiratory and pulmonary inhalation, stratum-corneum ablation by ultrasound, chemicals, and mechanical abrasion, and kinetic/ballistic delivery; (3) antigens, adjuvants, and carriers such as DNA, messenger RNA, synthesized plasmids, chemokines, wet and dry aerosols, and pollen-grain and microparticle vectors; and (4) the clinical experience and humoral, cellular, and cytokine immune responses observed for many of these target tissues, technologies, constructs, and carriers. This report summarizes the presentations and discussions from the workshop (https://web.archive.org/web/20160228112310/https://www.blsmeetings.net/NucleicAcidDeliveryDevices/), which was webcast live in its entirety and archived online (http://videocast.nih.gov/summary.asp?live=16059).     

Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine,gender-neutral and multiple age cohort vaccination

BackgroundThe success of human papillomavirus (HPV) national immunization program depends on effective strategies in optimizing the uptake of HPV vaccine. Given the increasing number of economic evaluations, this review was conducted to update the economic evidence on HPV vaccination, by focusing on: (i) 9-valent vaccine compared to bi- or quadrivalent vaccine; (ii) gender-neutral vaccination compared to female only vaccination; and (iii) multiple age cohort immunization compared to single age cohort immunization.MethodsSearches were performed until June 2016 using 4 databases: PubMed; Embase; Cochrane Library; and LILACS. The combined WHO, Drummond and CHEERS checklist were used to evaluate the quality of included studies.ResultsThirty-four studies were included in the review and most of them were conducted in high-income countries. The inclusion of adolescent boys in vaccination program was found to be cost-effective if vaccine price and coverage was low. When coverage for female was above 75%, gender-neutral vaccination was less cost-effective than when targeting only girls aged 9–18 years. Current evidence does not show conclusive proof of greater cost-effectiveness of 9-valent vaccine compared to the older HPV vaccines as the price for 9-valent vaccine was still uncertain. Multicohort immunization strategy was cost-effective in the age range 9–14 years but the upper age limit at which vaccination was no longer cost-effective needs to be further investigated. Key influential parameters identified were duration of vaccine protection, vaccine price, coverage, and discounting rates.ConclusionsThese findings are expected to support policy-makers in making recommendations for HPV immunization programs on either switching to the 9-valent vaccine or inclusion of adolescent boys’ vaccination or extending the age of vaccination.